Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food, gender, and age effect on Usmarapride PK
NCT03031574Phase 1Completed
- Sponsor
- Suven Life Sciences
- Start
- Jan 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of usmarapride in Alzheimer's disease (AD) and schizophrenia (3 arms), sponsored by Suven Life Sciences. Primary endpoints: Area under concentration at 72 hours and Maximum observed concentration at Day 1. Started Jan 2017; status: completed.
02
Drugs
usmarapride
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NCT03031574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031574.